Montelukast Glenmark (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelukast Glenmark, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast Glenmark, a leukotriene receptor antagonist, is used to manage conditions mediated by cysteinyl leukotrienes.

- Asthma: improves symptom control and reduces the frequency of wheezing episodes. - Allergic rhinitis: relieves nasal congestion, sneezing and itching. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often transient. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: occasional irritation of the throat. - Nausea: feeling of unease or urge to vomit. - Sore throat: mild irritation of the pharynx. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema or anaphylaxis. - Mood changes: depression, anxiety or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Stevens‑Johnson syndrome: severe skin and mucous membrane disorder. - Anaphylactic shock: rapid onset of severe allergic response.

When prescribing Montelukast, clinicians should consider several safety measures.

- Assess liver function: monitor transaminases in patients with hepatic disease. - Review psychiatric history: observe for mood alterations or suicidal ideation. - Avoid use in patients with known hypersensitivity to montelukast or its excipients. - Use with caution in children under 12 for asthma control: follow pediatric dosing guidelines. - Store at room temperature: keep in the original pack, protect from moisture and light.

Montelukast may interact with other medicines, requiring attention to potential changes in efficacy or safety.

Major Interactions (Avoid): - Ritonavir: may increase montelukast plasma concentrations. - Phenobarbital: may reduce montelukast effectiveness. - Carbamazepine: may lower drug exposure.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, requiring coagulation monitoring. - Theophylline: monitor for additive bronchospasm risk.